These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 728901)

  • 1. DIVEMA-methotrexate: immune-adjuvant role of polymeric carriers linked to antitumor agents.
    Przybylski M; Zaharko DS; Chirigos MA; Adamson RH; Schultz RM; Ringsdorf H
    Cancer Treat Rep; 1978 Nov; 62(11):1837-43. PubMed ID: 728901
    [No Abstract]   [Full Text] [Related]  

  • 2. Response of murine leukemia to combined BCNU-maleic anhydride-vinyl ether (MVE) adjuvant therapy and correlation with macrophage activation by MVE in the in vitro growth inhibition assay.
    Dean JH; Padarathsingh ML; Keys L
    Cancer Treat Rep; 1978 Nov; 62(11):1807-16. PubMed ID: 728898
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunomodulatory effect of various molecular-weight maleic anhydride-divinyl ethers and other agents in vivo.
    Chirigos MA; Stylos WA
    Cancer Res; 1980 Jun; 40(6):1967-72. PubMed ID: 7371032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical and biological adjuvants capable of potentiating tumor cell vaccine.
    Chirigos MA; Stylos WA; Schultz RM; Fullen JR
    Cancer Res; 1978 Apr; 38(4):1085-91. PubMed ID: 416906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CP-20,961: a structurally novel, synthetic adjuvant.
    Niblack JF; Otterness IG; Hemsworth GR; Wolff JS; Hoffman WW; Kraska AR
    J Reticuloendothel Soc; 1979 Dec; 26(Suppl):655-66. PubMed ID: 522084
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytotoxicity of adriamycin combined with methotrexate against L1210 leukemia in mice.
    Valeriote F; Vietti T; Coulter D
    J Natl Cancer Inst; 1980 Apr; 64(4):801-5. PubMed ID: 6928994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antitumor activity of polyanion and its application for drug delivery system of antitumor drugs].
    Hirano T; Ohashi S; Todoroki T; Inaba M; Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):542-7. PubMed ID: 2138872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyran (MVE-5) reverses the inhibition of macrophage receptors for cytophilic antibody induced by soluble immune complexes.
    Rao VS; Mitchell MS
    J Biol Response Mod; 1983; 2(1):67-80. PubMed ID: 6606020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokinetic response of activated macrophages to soluble products of neoplastic cells.
    Snodgrass MJ; Harris TM; Kaplan AM
    Cancer Res; 1978 Sep; 38(9):2925-9. PubMed ID: 679201
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of inoculation with neuraminidase-treated tumor cells on macrophage cytotoxicity in vitro.
    Alley CD; Snodgrass MJ
    Cancer Res; 1978 Aug; 38(8):2332-8. PubMed ID: 667829
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of maleic anhydride-divinyl ether copolymers on experimental M109 metastases and macrophage tumoricidal function.
    Pavlidis NA; Schultz RM; Chirigos MA; Luetzeler J
    Cancer Treat Rep; 1978 Nov; 62(11):1817-22. PubMed ID: 728899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific potentiation of L1210 vaccine by pyran copolymer.
    Mohr SJ; Chirigos MA; Smith GT; Fuhrman FS
    Cancer Res; 1976 Jun; 36(6):2035-9. PubMed ID: 1268855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage involvement in the protective effect of pyran copolymer against the Madison lung carcinoma (M109).
    Schultz RM; Papamatheakis JD; Luetzeler J; Ruiz P; Chirigos MA
    Cancer Res; 1977 Feb; 37(2):358-64. PubMed ID: 832262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine.
    Semon JH; Grindey GB
    Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-cytotoxic activity of pyran copolymer-induced macrophages associated with potentiation of tumour vaccine in recipient mice.
    Kataoka T; Oh-hashi F
    Cancer Immunol Immunother; 1985; 20(1):69-74. PubMed ID: 2998590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific in vivo inhibition of macrophage receptors for cytophilic antibody by soluble immune complexes.
    Rao VS; Grodzicki RL; Mitchell MS
    Cancer Res; 1979 Jan; 39(1):174-82. PubMed ID: 761189
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice.
    Zaharko DS; Covey JM
    Cancer Treat Rep; 1984 Oct; 68(10):1255-64. PubMed ID: 6084549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical and biological properties of cyclopolymers related to DIVEMA ("pyran copolymer").
    Butler GB; Xing Y; Gifford GE; Flick DA
    Ann N Y Acad Sci; 1985; 446():149-59. PubMed ID: 2409879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of molecular weight to antiviral and antitumor activities and toxic effects of maleic anhydride-divinyl ether (MVE) polyanions.
    Morahan PS; Barnes DW; Munson AE
    Cancer Treat Rep; 1978 Nov; 62(11):1797-803. PubMed ID: 103618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental chemotherapy (L1210) with 5-aza-2'-deoxycytidine in combination with pyran copolymer (MVE-4), an immune adjuvant.
    Zaharko DS; Covey JM; Muneses CC
    J Natl Cancer Inst; 1985 Jun; 74(6):1319-24. PubMed ID: 2582176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.